Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1]
NCT ID: NCT04360226 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

Start date: December 14, 2020
Phase:
Study type: Observational

This is an international, mulitcentre, observational, prospective study into Peak Inspiratory Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics of these groups. B) Assess the clinical role of PIF and inhaler choice in predicting COPD exacerbations and symptom burden. C) Assess the variability and correlation of PIF with other lung function measurements and CAT score in stable COPD. It is a 12 month study comprising one baseline assessment and 2 follow-up visits at 6 and 12 months.

NCT ID: NCT04206046 Active, not recruiting - Clinical trials for Arthroplasty, Replacement, Knee

The Effect of Regional Anaesthesia and Genetic Factors in the Development of Chronic Pain Following Total Knee Arthroplasty

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The study aims to assess the effect of spinal anaesthesia against a general anaesthesia with a femoral block, with respect to the incidence of chronic pain following a total knee replacement. It will also focus on genetic factors and their influence on chronic pain.

NCT ID: NCT00099437 Active, not recruiting - Breast Cancer Clinical Trials

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

CONFIRM
Start date: February 13, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.